cladribine has been researched along with Lymphoma, Follicular in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elinder, G; Kimby, E; Sverrisdottir, A | 1 |
| Armitage, JO; Hoelzer, D; Rummel, MJ; Tobinai, K | 1 |
| Kobayashi, M; Mizoroki, F; Nagasaki, E; Nozato, A; Okawa, Y; Shimada, T | 1 |
| Akaogi, T; Hayashi, H; Horiike, S; Kimura, S; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murotani, Y; Nomura, K; Sako, M; Sawai, N; Shimazaki, C; Taniwaki, M; Yoshikawa, T | 1 |
| Lärfars, G; Samuelsson, J; Udén-Blohmé, AM | 1 |
| Bashford, J; Bunce, I; Dodds, A; Eliadis, P; Firkin, F; Frost, T; Goldstein, D; Grigg, A; Kelly, C; Kimber, R; Lee, N; Lowenthal, R; Moore, D; Morton, J; Mulligan, S; Parkin, J; Rentoul, A; Rodwell, R; Rooney, K; Stone, J; Taylor, K; Wright, S | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Rummel, MJ; Schneider, B; Seipelt, G; Sommerlad, WD; Weidmann, E | 1 |
| Beutler, E; Carrera, CJ; Carson, DA; Kay, AC; Piro, LD; Saven, A; Thurston, D | 1 |
1 review(s) available for cladribine and Lymphoma, Follicular
| Article | Year |
|---|---|
Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mitoxantrone; Treatment Outcome | 2004 |
1 trial(s) available for cladribine and Lymphoma, Follicular
| Article | Year |
|---|---|
2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Topics: 2-Chloroadenosine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bacterial Infections; Bone Marrow Diseases; Cladribine; Deoxyadenosines; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Treatment Outcome | 1992 |
6 other study(ies) available for cladribine and Lymphoma, Follicular
| Article | Year |
|---|---|
Safety of rituximab therapy during the first trimester of pregnancy: a case history.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant, Newborn; Lymphoma, Follicular; Male; Methotrexate; Mitoguazone; Peripheral Blood Stem Cell Transplantation; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Remission Induction; Rituximab; Safety; Transplantation, Autologous; Vincristine | 2004 |
[Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma].
Topics: Antineoplastic Agents; Bone Marrow; Cladribine; Cryptococcosis; Humans; Lung Diseases, Fungal; Lymphoma, Follicular; Male; Middle Aged; Opportunistic Infections; Tomography, X-Ray Computed | 2006 |
[Combination therapy with rituximab and cladribine for patients with follicular lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Treatment Outcome | 2007 |
Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies.
Topics: Aged; Antineoplastic Agents; Cladribine; Eosinophilia; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Vidarabine | 1996 |
High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Opportunistic Infections; Recurrence; Survival Analysis; Thrombocytopenia; Treatment Outcome | 1996 |
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Burkitt Lymphoma; Caspase 7; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cladribine; Complement Activation; Complement System Proteins; Cysteine Proteinase Inhibitors; Doxorubicin; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Rabbits; Rituximab; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |